Tamoxifen Citrate Patent Expiration
Tamoxifen Citrate was first introduced by Astrazeneca Pharmaceuticals Lp
Tamoxifen Citrate Patents
Given below is the list of patents protecting Tamoxifen Citrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Soltamox | US6127425 | Oral liquid medicine solution |
Jun 26, 2018
(Expired) | Mayne Pharma Commrcl |
Tamoxifen Citrate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tamoxifen Citrate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |